Skip to main
ABSI

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci is a leading company in the growing field of AI-powered drug discovery and development, with a proven platform for creating novel biologics. Their lead candidate, ABS-201, has the potential to be a best-in-class therapy for a range of indications, including pattern hair loss and endometriosis. Although there are risks associated with clinical development and competition, Absci's differentiated platform and promising clinical data make us optimistic about their future success and the potential of their stock.

Bears say

Absci is a relatively new and unproven company with a high-risk profile due to its early stage clinical trials and lack of established market presence. Additionally, their lead product candidate, ABS-201, may face significant competition in the crowded market for hair loss and endometriosis treatments. Furthermore, the company's financials do not currently support their potential future valuation, making it a risky investment with a negative outlook.

Absci Corp (ABSI) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.